drugset / Trial / NCT00546104
Phase II Dasatinib Study in Advanced Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out if dasatinib will safely reduce the size or spread of your tumor.
Timeline
- Start
- 2007-10
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 50 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |